Search Clinical Trials in the European Union

3-6 months
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
201-220 of 331 trials

Preventing Chemotherapy-Induced Nausea in Children: IV NEPA Study

We are studying a new intravenous treatment for children with cancer to see if it can effectively prevent nausea and vomiting during chemotherapy. This trial compares IV NEPA with standard treatments to ensure safety and effectiveness.

Chemotherapy-Induced Nausea and Vomiting3-6 monthsEfficacy phase (II)Confirmation phase (III)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementOncologyPediatrics

Heart Health: Apixaban vs. Warfarin Study

We are comparing two medications to see which is more effective in resolving blood clots in patients with left ventricular thrombus after a heart attack. We're also looking at safety and bleeding risks associated with each treatment.

Acute Myocardial InfarctionLeft Ventricular Thrombosis3-6 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Metastatic Colorectal Cancer: Valproic Acid and Standard Treatment

We are studying a new combination of Valproic acid with standard therapies for patients with metastatic colorectal cancer who have already been treated. The goal is to see if this combination improves survival and quality of life compared to standard treatment alone.

Metastatic Colorectal Cancer3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyOncology

Compulsive Sexual Behavior Disorder: Medication Study

We are comparing the effects of escitalopram, naltrexone, and their combination on symptoms of compulsive sexual behavior. This study aims to understand how these treatments may improve daily functioning and emotional well-being.

Compulsive Sexual Behavior3-6 monthsConfirmation phase (III)Investigational MedicinesPsychiatry

Severe Autoimmune Encephalitis: Bortezomib Study

We are investigating whether bortezomib is effective and safe for patients with severe autoimmune encephalitis. This trial focuses on individuals with specific autoantibodies related to their condition.

Autoimmune Encephalitis3-6 monthsEfficacy phase (II)6-10 visitsStandard MedicinesCost ReimbursementNeurologyRheumatology

Focal Onset Seizures: Extended-Release Levetiracetam Study

We are testing a new once-daily version of levetiracetam for people with drug-resistant focal onset seizures. The study aims to see if it reduces seizure frequency better than current treatments and a placebo.

Refractory Epilepsy3-6 monthsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Psoriatic Arthritis and Axial Spondyloarthritis: Sonelokimab Study

We are exploring how sonelokimab affects disease activity in patients with active psoriatic arthritis or axial spondyloarthritis. This study will help us understand its potential benefits and safety.

Axial SpondyloarthritisPsoriatic Arthritis3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesInternal MedicineRheumatology

Hidradenitis Suppurativa: AVTX-009 Treatment Study

We are evaluating a new treatment, AVTX-009, for individuals with moderate to severe hidradenitis suppurativa. The goal is to see if it works better than a placebo and to check its safety.

Hidradenitis Suppurativa3-6 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteDermatologyInternal Medicine

Alzheimer's Dementia: ITI-1284 for Agitation

We are studying whether ITI-1284 can help reduce agitation in patients with Alzheimer's dementia compared to a placebo. The trial will also assess the safety and tolerability of this new treatment.

Alzheimer's Disease3-6 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPsychiatry

Painful Diabetic Peripheral Neuropathy: VX-993 Study

We are evaluating a new oral medication, VX-993, for people with pain from diabetic peripheral neuropathy. The study aims to determine if it effectively reduces pain and is safe to use.

Diabetic Peripheral Neuropathic Pain3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementDiabetologyNeurology

Juvenile Idiopathic Arthritis: Early Drug Withdrawal Study

We are exploring whether stopping medication early is safe and effective for children with juvenile idiopathic arthritis in remission. This study also aims to identify new biomarkers that may help predict flare-ups after treatment withdrawal.

Juvenile Idiopathic Arthritis3-6 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesPediatricsRheumatology

Lupus Nephritis: MSV-ALLO® Treatment Study

We are testing a new cell therapy for lupus nephritis to see if it helps patients achieve remission. The study compares this treatment to a placebo to evaluate its safety and effectiveness.

Lupus Nephritis3-6 monthsEfficacy phase (II)Confirmation phase (III)11-15 visitsInvestigational MedicinesNephrologyRheumatology

Short Course Antibiotics for Gram-Negative Bacteremia

We are studying whether a 5-day antibiotic treatment is as effective and safe as longer treatments for hospitalized adults with Gram-negative bacteremia from urinary tract infections.

Gram-negative Bacteremia3-6 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteInfectious DiseasesInternal Medicine

Sepsis-Induced Hypotension: REGN7544 Treatment Study

We are studying REGN7544 to see if it can help adults with sepsis-induced hypotension manage their blood pressure and reduce the need for other medications. The trial will also assess the safety and effects of this treatment.

Sepsis-Induced Hypotension3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInfectious Diseases

Staphylococcus Aureus Bloodstream Infections: Dalbavancin Study

We are testing a single dose of intravenous Dalbavancin against standard antibiotics for patients with bloodstream infections. The goal is to see if Dalbavancin is as effective and to evaluate its impact on recovery and quality of life.

Catheter-Related Bloodstream Infections3-6 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteInfectious DiseasesInternal Medicine

Rheumatoid Arthritis: AP1189 with Methotrexate

We are studying a new oral medication, AP1189, for people with early rheumatoid arthritis who haven't received other treatments. The goal is to see if it works better with methotrexate than methotrexate alone.

Rheumatoid Arthritis3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementRheumatology

Chronic Cough: Taplucainium Inhalation Powder

We are studying a new inhalation powder for adults with chronic cough that hasn't improved with other treatments. The trial will evaluate its effects on cough frequency and quality of life compared to a placebo.

Refractory or Unexplained Chronic Cough3-6 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicinePulmonology

Breast Cancer Treatment: I-BCT-1 Study

We are exploring how genetic changes in breast tumors can help select the best treatment options for patients. This study includes patients with neoadjuvant and metastatic breast cancer to improve therapy outcomes.

Breast Cancer3-6 monthsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Intravenous Iron for Mobility After Hip Fracture Surgery

We are studying whether a single dose of intravenous iron helps elderly patients recover mobility after hip fracture surgery. The trial will also assess its effects on anemia, fatigue, and quality of life.

Hip Fracture3-6 monthsMonitoring phase (IV)≤5 visitsStandard MedicinesInternal MedicineOrthopedics and Traumatology

Rabies Vaccine: Pain and Usability Study for Kids

We are exploring how different injection methods affect pain and anxiety in children aged 4 to 14 receiving a rabies vaccine. Parents will also share their observations about their child's experience.

Rabies Pre-Exposure Prophylaxis3-6 monthsConfirmation phase (III)Monitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementInfectious DiseasesPediatrics